Bioventures In Japan Look Abroad To License Promising Drugs
This article was originally published in PharmAsia News
Executive Summary
Japanese bioventure firms are reversing a trend and beginning to license their own drugs to foreign pharmaceutical companies. Such deals normally have involved large Japanese drug makers licensing drugs from abroad, but now foreign drug makers are looking to Japan-based bioventures. Evec, a Japanese bioventure, was an early licenser, reaching an agreement with Boehringer Ingelheim of Germany to develop and market its antibody agent. Other Japanese bioventures have been licensing their drugs to larger Japanese drug makers. (Click here for more - a subscription may be required